Plasma and cerebrospinal fluid pharmacokinetics of the histone deacetylase inhibitor, belinostat (PXD101), in non-human primatesWARREN, Katherine E; MCCULLY, Cindy; DVINGE, Henrik et al.Cancer chemotherapy and pharmacology. 2008, Vol 62, Num 3, pp 433-437, issn 0344-5704, 5 p.Article

A sensitive and specific liquid chromatography-tandem mass spectrometric method for determination of belinostat in plasma from liver cancer patientsWANG, Ling-Zhi; DANIEL CHAN; WINNIE YEO et al.Journal of chromatography. B. 2010, Vol 878, Num 26, pp 2409-2414, issn 1570-0232, 6 p.Article

Activity of the histone deacetylase inhibitor belinostat (PXD101) in preclinical models of prostate cancerXIAOZHONG QIAN; ARA, Gulshan; MILLS, Evan et al.International journal of cancer. 2008, Vol 122, Num 6, pp 1400-1410, issn 0020-7136, 11 p.Article

Monitoring the effect of belinostat in solid tumors by H4 acetylationMARQUARD, Lena; PETERSEN, Kamille Dumong; PERSSON, Morten et al.APMIS. Acta pathologica, microbiologica et immunologica Scandinavica. 2008, Vol 116, Num 5, pp 382-392, issn 0903-4641, 11 p.Article

Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer modelsLUCA GRAVINA, Giovanni; MARAMPON, Francesco; GIUSTI, Ilaria et al.International journal of oncology. 2012, Vol 40, Num 3, pp 711-720, issn 1019-6439, 10 p.Article

Bortezomib interacts synergistically with belinostat in human acute myeloid leukaemia and acute lymphoblastic leukaemia cells in association with perturbations in NF-κB and BimYUN DAI; SHUANG CHEN; LI WANG et al.British journal of haematology. 2011, Vol 153, Num 2, pp 222-235, issn 0007-1048, 14 p.Article

A Phase 1 Pharmacokinetic and Pharmacodynamic Study of the Histone Deacetylase Inhibitor Belinostat in Patients with Advanced Solid TumorsSTEELE, Nicola L; PLUMB, Jane A; DEBONO, Johann S et al.Clinical cancer research. 2008, Vol 14, Num 3, pp 804-810, issn 1078-0432, 7 p.Article

Interactions between Bortezomib and Romidepsin and Belinostat in Chronic Lymphocytic Leukemia CellsYUN DAI; SHUANG CHEN; KRAMER, Lora B et al.Clinical cancer research. 2008, Vol 14, Num 2, pp 549-558, issn 1078-0432, 10 p.Article

Belinostat: First Global ApprovalPOOLE, Raewyn M.Drugs (Basel). 2014, Vol 74, Num 13, pp 1543-1554, issn 0012-6667, 12 p.Article

Developing Histone Deacetylase Inhibitors as Anti-Cancer Therapeutics : Targeted Cancer Therapies: Current Status and Future DirectionsVENUGOPAL, B; EVANS, T. R. J.Current medicinal chemistry. 2011, Vol 18, Num 11, pp 1658-1671, issn 0929-8673, 14 p.Article

A phase I study of the safety and pharmacokinetics of the histone deacetylase inhibitor belinostat administered in combination with carboplatin and/or paclitaxel in patients with solid tumoursLASSES, U; MOLIFE, L. R; KNOBLAUCH, P et al.British journal of cancer. 2010, Vol 103, Num 1, pp 12-17, issn 0007-0920, 6 p.Article

Pharmacokinetic and pharmacodynamic properties of an oral formulation of the histone deacetylase inhibitor Belinostat (PXD101)STEELE, N. L; PLUMB, J. A; VIDAL, L et al.Cancer chemotherapy and pharmacology. 2011, Vol 67, Num 6, pp 1273-1279, issn 0344-5704, 7 p.Article

Belinostat and panobinostat (HDACI): in vitro and in vivo studies in thyroid cancerDANIEL CHAN; YUN ZHENG; TYNER, Jeffrey W et al.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 9, pp 1507-1514, issn 0171-5216, 8 p.Article

Phase II Study of Belinostat in Patients With Recurrent or Refractory Advanced Thymic Epithelial TumorsGIACCONE, Giuseppe; RAJAN, Arun; SPITTLER, John et al.Journal of clinical oncology. 2011, Vol 29, Num 15, pp 2052-2059, issn 0732-183X, 8 p.Article

Inhibiting proliferation of gefitinib-resistant, non-small cell lung cancerSUDO, Makoto; TAN MIN CHIN; MORI, Seiichi et al.Cancer chemotherapy and pharmacology. 2013, Vol 71, Num 5, pp 1325-1334, issn 0344-5704, 10 p.Article

Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumoursMACKAY, Helen J; HIRTE, Hal; PAN, James et al.European journal of cancer (1990). 2010, Vol 46, Num 9, pp 1573-1579, issn 0959-8049, 7 p.Article

Epigenetic Therapy Using Belinostat for Patients With Unresectable Hepatocellular Carcinoma: A Multicenter Phase I/II Study With Biomarker and Pharmacokinetic Analysis of Tumors From Patients in the Mayo Phase II Consortium and the Cancer Therapeutics Research GroupYEO, Winnie; CHUNG, Hyun C; HUI, Edwin P et al.Journal of clinical oncology. 2012, Vol 30, Num 27, pp 3361-3367, issn 0732-183X, 7 p.Article

HDAC inhibitors : Clinical update and mechanism-based potentialGLASER, Keith B.Biochemical pharmacology. 2007, Vol 74, Num 5, pp 659-671, issn 0006-2952, 13 p.Article